**
Palantir Technologies, the US-based data analytics firm, finds itself at the centre of a heated debate as UK ministers contemplate the future of a £330 million contract involving the National Health Service (NHS). The contract, aimed at delivering a Federated Data Platform (FDP) to integrate various health data systems across the NHS, has come under fire from various ideological groups. Louis Mosley, Palantir’s UK executive vice-chair, has urged the government to resist pressure to terminate the agreement, warning that such a move could undermine patient care and hinder critical advancements in the NHS.
The Controversial Federated Data Platform
The Federated Data Platform is designed to enhance the NHS’s ability to connect and manage disparate health information through advanced analytics. As Palantir also maintains contracts with the UK’s Ministry of Defence and several police forces, its involvement in the public sector has raised eyebrows. Critics argue that the company’s ties to military and intelligence operations in the US and Israel pose ethical concerns regarding data privacy and patient trust.
Mosley emphasised the importance of maintaining the contract, asserting that the software has already demonstrated substantial benefits. “The clear evidence of the past two years of delivery is that our software is helping. It is forecast to deliver £150 million in benefits by the end of the decade, representing a £5 return for every pound spent,” he stated. His comments come as the government considers invoking a break clause in the contract, which would allow for its termination once it becomes active next year.
Political Repercussions and Public Sentiment
The UK government’s deliberations reflect a broader unease about the implications of partnering with a firm like Palantir. Health officials have expressed concern that the company’s controversial reputation may affect the successful delivery of the FDP. As criticism mounts, even voices within the Labour Party are voicing apprehensions over the deal, highlighting a shift in public sentiment regarding the involvement of technology firms in essential public services.
Health Secretary Wes Streeting acknowledged the concerns during a recent podcast interview, noting the ideological leanings of Palantir’s founders. He stated, “When you look at some of the things Palantir’s leaders have said in the States… if you were to put [Peter Thiel] and some of those Palantir bosses on the political spectrum in the UK, they would be well off to the right of even Kemi Badenoch’s Conservative party.” However, he reassured listeners that Palantir does not access patient data, stating, “The platform they have given to us to improve our systems and performances… is run by us. Palantir don’t see our patient data.”
Increasing Opposition from Healthcare Professionals
Opposition to Palantir’s NHS involvement has been vocal, particularly from organisations like the British Medical Association (BMA), which has long resisted the use of private companies in patient care. The BMA’s stance underscores a growing concern among healthcare professionals regarding the ethical implications of outsourcing sensitive health data management to a company with military ties.
Recent demonstrations by pro-Palestinian NHS workers have further highlighted the discontent surrounding Palantir’s contracts, reflecting broader societal concerns about corporate influence in public health. As more NHS organisations adopt Palantir’s technology—rising from 118 to 151 since June—these tensions are likely to escalate, particularly as the target for NHS organisations using the platform remains unmet.
Why it Matters
The ongoing debate surrounding Palantir’s role in the NHS encapsulates a pivotal moment in the intersection of technology and public healthcare. As the UK grapples with issues of data privacy, corporate ethics, and the implications of advanced technology in vital sectors, this situation highlights the need for transparency and ethical considerations in governmental contracts. The outcome of this scrutiny could set a precedent for how technology firms engage with public institutions in the future, shaping the landscape of healthcare delivery in the UK and perhaps influencing similar discussions globally.
